Vaccinex and Janssen enter into a collaboration for the creation of novel anti-cancer agents

News provided by

Dec 02, 2014, 10:15 ET

ROCHESTER, N.Y., Dec. 2, 2014 /PRNewswire/ -- Vaccinex, Inc. announced today that it has entered into a research collaboration with Janssen Research & Development, LLC, a Pharmaceutical Company of Johnson & Johnson, for the creation of novel anti-cancer agents. The terms of the collaboration were not disclosed.

Based in Rochester, New York, Vaccinex is a privately held clinical-stage biotechnology company engaged in the discovery and development of human therapeutic monoclonal antibodies to treat cancer and neurodegenerative diseases, including multiple sclerosis and Huntington's disease. Vaccinex has developed proprietary technology to create high quality cDNA libraries in a vaccinia virus-based vector, and has utilized this technology both for target identification and in its ActivMAb^® Antibody Discovery Technology. The company utilizes its ActivMAb^® technology for rapid, mammalian cell-based antibody selection to build its own therapeutic antibody pipeline and in service to its biopharmaceutical partners. For more information and to contact Vaccinex, visit www.vaccinex.com.

Logo- http://photos.prnewswire.com/prnh/20101101/NY92716LOGO

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/vaccinex-and-janssen-enter-into-a-collaboration-for-the-creation-of-novel-anti-cancer-agents-300003359.html

SOURCE Vaccinex, Inc.